Tyme Technologies, Inc. (TYME): Price and Financial Metrics
GET POWR RATINGS... FREE!
TYME Stock Price Chart Interactive Chart >
TYME Price/Volume Stats
|Current price||$0.31||52-week high||$1.14|
|Prev. close||$0.29||52-week low||$0.22|
|Day high||$0.32||Avg. volume||1,009,732|
|50-day MA||$0.30||Dividend yield||N/A|
|200-day MA||$0.37||Market Cap||53.50M|
Tyme Technologies, Inc. (TYME) Company Bio
Tyme Technologies, Inc., a clinical-stage pharmaceutical company, focuses on the discovery and development of cancer therapeutics for various oncology indications. It is developing SM-88, a combination therapy in Phase II development for prostate cancer. The company was founded in 2011 and is based in New York, New York.
Most Popular Stories View All
TYME Latest News Stream
|Loading, please wait...|
TYME Latest Social Stream
View Full TYME Social Stream
Latest TYME News From Around the Web
Below are the latest news stories about TYME TECHNOLOGIES INC that investors may wish to consider to help them evaluate TYME as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them!
Syros and Tyme Technologies Announce Stockholder Approval of Merger
-- Combined Company to Trade on Nasdaq Under Ticker “SYRS” ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 20
TYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and Tyme
BEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co. (“Glass Lewis”) and Institutional Shareholder Services Inc. (“ISS”) have recommended that Tyme stockholders vote “FOR” the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. (“Syros”) and “FOR” all other matters to be voted upon at the Company’s upcoming Special Meeting of Stockholders (the
Mass. M&A activity picks up among life sciences firms
Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come.
Syros to acquire New Jersey biotech Tyme Technologies
Syros Pharmaceuticals is set to acquire a New Jersey biotech firm called Tyme Technologies Inc., extending its cash runway into 2025 at a time when biotech stocks are being hammered.
TYME Price Returns
Loading social stream, please wait...